Abstract
Background Depression remains an unresolved issue on a global scale. Recently, a novel concept of ‘anti-inflammatory-based pharmacotherapy’ has been developed. Despite the role of inflammation in depression having been discussed in many reviews at various levels, the prevalence of this new concept in randomised controlled clinical studies and its implications remain elusive. The aim of this scoping review was precisely to explore in depth the current status of inflammation in randomised controlled clinical trial studies of depression.
Methods PubMed was systematically searched from inception to December 11 2024. Studies that researches on the treatment of depression based on anti-inflammatory strategies were included. Study characteristics and outcomes were extracted and organized thematically.
Findings 11 reports of randomised controlled clinical trials were included, which accumulated 119 depressed patients. All studies found that there is a connection between the effects of anti-inflammatory drugs in treating depression and a large decrease in the levels of inflammatory markers in the blood of depressed patients compared to before treatment. Three inflammatory markers, CRP, IL-6 and TNF-alpha, were the most frequently mentioned. The current strategy of anti-inflammatory drug administration did not differ fundamentally from the previous strategy of traditional antidepressant drugs combined with psychotherapy.
Interpretation At present, the use of anti-inflammatory strategies for the pharmacological treatment of depression has limited research value and poor feasibility. The future direction of the new concept of anti-inflammatory strategies for the treatment of depression, proposed in the context of the association between inflammation and depression, is that psychiatrists, researchers, and psychotherapists should shift their future focus from pharmacological treatments based on anti-inflammatory strategies to non-pharmacological treatments of anti-inflammatory strategies, such as positive thinking, exercise, and so on. The popularity of purely clinical randomised controlled studies in the depression population is extremely low when considering the financial investment in research and the benefits of translating the results. In the future, public interest studies, low research costs, and research protocols with mass generalisability will be more likely to stimulate the depression community’s interest in participating in research. The potential value and feasibility of future research lies in the application of an integrated AI platform to assist pharmacological treatment of depression based on anti-inflammatory strategies.
Registration DOI: https://doi.org/10.17605/OSF.IO/A64GC
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://doi.org/10.17605/OSF.IO/A64GC
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a scope review in which the literature data used were ethically approved. Therefore, no additional ethical approval is required for our research. The scope review has been registered.The study has been registered on the Open Science Framework (OSF) platform at the following address: osf.io/k9pue. Registration DOI: https://doi.org/10.17605/OSF.IO/A64GC
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
A new figure was added on the basis of the original draft (named Figure 1 in the revised draft), and figure 2 in the original draft (named Figure 3 in the revised draft) was modified. The remaining changes were mentioned in the supplementary document.
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviation
- AI
- artificial intelligence
- NSAIDs
- non-steroidal anti-inflammatory drugs
- NLRP3
- nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3
- HSPs
- heat shock proteins
- ROS
- reactive oxygen species
- SNS
- sympathetic nervous system
- HPA
- hypothalamic-pituitary-adrenal
- BBB
- blood-brain barrier
- DAMPs
- damage-associated molecular patterns
- BDNF
- brain-derived neurotrophic factor
- IL-1β
- interleukin-1 beta
- TNF-α
- tumor necrosis factor-alpha
- IL-6
- interleukin-6
- NTS
- nucleus tractus solitarius
- MMPs
- matrix metalloproteinases
- Evs
- extracellular vesicles
- miRNAs
- microRNAs
- RCT
- randomized controlled trial
- DSM-IV
- Diagnostic and Statistical Manual of Mental Disorders-IV
- DSM-V
- Diagnostic and Statistical Manual of Mental Disorders-V
- CRP
- C-reactive protein
- hs-CRP
- high-sensitivity C-reactive protein
- sTNFR1
- soluble tumor necrosis factor receptor 1
- sTNFR2
- soluble tumor necrosis factor receptor 2
- IFN-γ
- interferon-γ
- IL-1β
- interleukin-1β
- IL-4
- interleukin-4
- IL-8
- interleukin-8
- IL-10
- interleukin-10
- IL-12p70
- interleukin-12p70
- IL-13
- interleukin-13
- GZA
- glycopyrrolate
- SSRI
- selective serotonin reuptake inhibitor
- MDA
- malondialdehyde
- PRISMA
- preferred reporting items for systematic reviews and meta-analyses
- GRIPP2
- guidance for reporting involvement of patients and the public version 2
- JBI
- joanna briggs institute
- OSF
- Open Science Framework
- NF-κB
- nuclear factor kappa-B
- P2X7R
- P2X purinoceptor 7
- SGLT2
- sodium-glucose cotransporter 2
- AMPK
- AMP-activated protein kinase
- BDNF
- brain-derived neurotrophic factor
- TrkB
- tropomyosin receptor kinase B
- PI3K
- phosphatidylinositol 3-kinase
- Akt
- protein kinase B
- ASC
- apoptosis-associated speck-like protein containing a CARD
- TLR4
- toll-like receptor 4
- FoxO1
- forkhead box O1
- CREB
- cyclic AMP response element-binding protein
- CRS
- chronic restraint stress
- SGKL
- liver-sparing granules
- PBM
- brain-gut photobiomodulation
- PKCζ
- protein kinase C zeta
- ERVs
- endogenous retroviruses
- BLA
- basolateral amygdala
- LT
- leukotrienes
- TNF-alpha
- tumor necrosis factor-alpha
- LPS
- lipopolysaccharide
- PUFAs
- n-3 polyunsaturated fatty acids
- CUMS
- chronic unpredictable mild stress
- DRAP
- direct rapid acting parenteral
